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Statin Eligibility, Coronary Artery Calcium, and Subsequent
Cardiovascular Events According to the 2016 United States
Preventive Services Task Force (USPSTF) Statin Guidelines:
MESA (Multi-Ethnic Study of Atherosclerosis)
Michael D. Miedema, MD, MPH; Zeina A. Dardari, MS; Sina Kianoush, MD, MPH; Salim S. Virani, MD, PhD; Joseph Yeboah, MD, MS;
Thomas Knickelbine, MD; Veit Sandfort, MD; Carlos J. Rodriguez, MD, MPH; Khurram Nasir, MD, MPH; Michael J. Blaha, MD, MPH
Background-—The potential impact of the 2016 United States Preventive Services Task Force (USPSTF) guidelines on statins for
primary prevention of atherosclerotic cardiovascular disease (ASCVD) warrants further analysis.
Methods and Results-—We studied participants from MESA (Multi-Ethnic Study of Atherosclerosis) aged 40 to 75 years and not on
statins. We compared statin eligibility at baseline (2000–2002) and over follow-up between USPSTF and the 2013 American College
of Cardiology/American Heart Association (ACC/AHA) guidelines. Coronary artery calcium (CAC) was measured at baseline.
Absolute ASCVD event rates were calculated according to eligibility categories for each guideline. Among 4962 MESA participants
(aged 59.38.8 years, 47.2% female), compared with ACC/AHA guidelines, baseline statin eligibility by USPSTF was significantly
lower (34.4% versus 49.1%) and increased less over time (39.1% versus 59.1%) at examination 5 [years 2010–2012]). Compared with
ACC/AHA, participants eligible by USPSTF were less likely to have zero CAC at baseline (36.6% versus 41.2%) and had higher rates of
hard ASCVD events per 1000 person-years (11.6 [95% confidence interval, 10.2–13.3] versus 10.0 [8.9–11.3]). The hard ASCVD
event rate in those eligible by ACC/AHA but not USPSTF was 6.5 (4.9–8.5) events per 1000 person-years, with the rate varying
significantly according to baseline CAC (4.2 [2.7–6.7] events in those with CAC=0, 12.8 [8.3–19.9] events in those with CAC >100).
Conclusions-—In MESA, compared with ACC/AHA, the USPSTF statin guidelines resulted in a 15% absolute decrease in eligibility.
Participants with discordant eligibility had ASCVD rates that varied significantly according to baseline CAC, suggesting CAC could
aid clinical decision making for statins in these individuals. ( J Am Heart Assoc. 2018;7:e008920. DOI: 10.1161/JAHA.118.
008920.)
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I n 2016, the United States Preventive Services Task Force(USPSTF) released guidelines on statin use for the primary
prevention of atherosclerotic cardiovascular disease
(ASCVD).1 These guidelines recommended that individuals
aged 40 to 75 years with 1 or more major ASCVD risk factors
(hypertension, tobacco use, diabetes mellitus, or dyslipidemia)
and a 10-year ASCVD risk ≥10% initiate statin therapy. Similar
to the USPSTF guidelines, the 2013 American College of
Cardiology (ACC)/American Heart Association (AHA) guideli-
nes for the treatment of blood cholesterol recommended a
risk-based approach to allocation of statin therapy in primary
prevention,2 with an important focus on a clinician–patient
risk discussion before initiation of statin therapy.3 The ACC/
AHA guidelines identified a lower threshold for initiating statin
therapy compared with the USPSTF guidelines, recommend-
ing statins for individuals with a 10-year ASCVD risk ≥7.5%.
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Importantly, the presence of 1 major ASCVD risk factor is not
required by the ACC/AHA guidelines, leading to the obser-
vation that individuals may be eligible for statin therapy based
on age alone.4 Prior studies have demonstrated that age plays
a significant role in determining statin eligibility according to
the ACC/AHA guidelines.5,6
Recent data from the National Health and Nutrition
Examination Survey (NHANES) estimated that 9 million
fewer middle-aged US adults are statin eligible using USPSTF
criteria compared with ACC/AHA guidelines.7 The implica-
tions of not recommending statin therapy for this significant
portion of the US population are unclear. The goal of this
analysis was to compare the prevalence of statin eligibility
according to the 2 guidelines in MESA (Multi-Ethnic Study of
Atherosclerosis) participants at baseline and over 4 follow-up
examinations as well as to analyze the prevalence of coronary
artery calcium (CAC) at baseline according to guideline
eligibility categories. Additionally, we sought to analyze
ASCVD event rates over time according to statin eligibility
categories within each guideline as well as in those individuals
with discordant recommendations.
Methods
Study Design and Participants
MESA is a community-based prospective cohort study of
asymptomatic individuals to determine factors associated
with the prevalence, incidence, progression, and implications
of subclinical and clinical ASCVD. Details of the MESA study
design and objectives have been previously reported.8 Briefly,
6814 participants aged 45 to 84 years old who were free of
clinical cardiovascular disease at baseline were enrolled
between 2000 and 2002 (baseline visit) at 6 US field centers
(Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles,
CA; New York, NY; and St. Paul, MN). Four additional follow-up
visits (examinations 2–5) were conducted in 2002 to 2004,
2004 to 2006, 2005 to 2007, and 2010 to 2012. This study
was approved by the institutional review boards at each
center and all participants provided written informed consent.
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Use of statin therapy, including frequency and dosage, was
evaluated by self-report and also review of pharmacy
containers for all medications used during the 2 weeks
preceding the MESA visit. Of the 6814 MESA participants at
baseline, we excluded 806 participants aged >75 years old
(both statin guidelines target individuals aged 40–75 years
old), 859 on statin therapy at baseline, 3 participants missing
statin use data, and 184 with a low-density lipoprotein
cholesterol (LDL-C) ≥190 mg/dL (both guidelines exclude
these individuals because of probable familial hypercholes-
terolemia), leaving 4962 individuals in the baseline analysis.
Measurement and Definition of CVD Risk Factors
Systolic and diastolic blood pressure were measured 3 times
using an automated sphygmomanometer (Dinamap, Critikon,
Tampa, FL), with 1-minute intervals, and the mean of the last 2
measurements was used. The Collaborative Studies Clinical
Laboratory at Fairview-University Medical Center (Minneapolis,
MN)measured concentrations of total and high-density lipopro-
tein cholesterol, triglycerides, and plasma glucose, after a 12-
hour fast. LDL-C was calculated using the Friedewald equation.
Traditional ASCVD risk factors were identified based on
definitions used by the USPSTF guidelines.1 Hypertension was
defined as a systolic blood pressure ≥140 mm Hg, or a
diastolic blood pressure ≥90 mm Hg, or antihypertensive
medication use. Diabetes mellitus was defined as a fasting
glucose of ≥7 mmol/L (126 mg/dL) or use of hypoglycemic
medication (oral agents and/or insulin). Dyslipidemia was
defined as an LDL-C >130 mg/dL or a high-density lipopro-
tein cholesterol <40 mg/dL. Tobacco use was defined as
current tobacco within the last 30 days of the time of the
baseline MESA examination.
Measurement of CAC
CAC is not included in the primary eligibility criteria for either
guideline. However, MESA includes CAC scores on everyone,
Clinical Perspective
What Is New?
• Using data from MESA (Multi-Ethnic Study of Atherosclero-
sis), we found that application of the United States
Preventive Services Task Force statin guidelines resulted
in a 15% absolute decrease in statin eligibility compared
with the 2013 American College of Cardiology/American
Heart Association guidelines.
• MESA participants with discordant statin eligibility accord-
ing to the 2 guidelines had atherosclerotic cardiovascular
disease events rates that varied significantly according to
baseline coronary artery calcium.
What Are the Clinical Implications?
• Healthcare providers and organizations should understand
that adoption of the USPSTF guidelines, compared to the
ACC/AHA guidelines, will lead to a significant decrease in
statin eligibility at a population level.
• For individuals with discordant statin recommendations,
coronary artery calcium testing may be useful as a tool to
guideline clinical decision making regarding statin use.
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enabling analysis of the burden of subclinical coronary
atherosclerosis in different eligibility categories for each
guideline. CAC scoring was performed with cardiac-gated
chest computed tomography (CT) utilizing either an electron-
beam CT scanner (Los Angeles, Baltimore, and New York) or a
multidetector CT system (Chicago, St. Paul, and Forsyth
County).9 All patients were scanned twice and CAC Agatston
scores were averaged. A cardiologist or radiologist interpreted
all scans at the MESA CT reading center (Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical
Center).
Assessing Statin Eligibility Based on the USPSTF
and the ACC/AHA Guidelines
As described in the guidelines for both the USPSTF and ACC/
AHA, 10-year ASCVD risk was calculated by the Pooled
Cohorts Equation (PCE),2 using data from the baseline MESA
examination on age, sex, race, total cholesterol, high-density
lipoprotein cholesterol, history of antihypertensive treatment,
and diabetes mellitus. Participants were considered eligible
according to the USPSTF guidelines if they had 1 or more
major ASCVD risk factors (hypertension, tobacco use,
diabetes mellitus, or dyslipidemia) and a 10-year ASCVD risk
≥10%. Participants with 1 major ASCVD risk factor and a
10-year risk of ≥7.5% and <10% were considered potentially
eligible and participants with ASCVD risk of <7.5% were
considered not eligible.1
For primary prevention in individuals with an LDL-C
<190 mg/dL, the ACC/AHA guidelines recommend moder-
ate- to high-intensity statin therapy for patients with diabetes
mellitus or individuals with an estimated 10-year ASCVD risk
≥7.5%. Per ACC/AHA guidelines, individuals with a 10-year
ASCVD risk ≥5% and <7.5% were considered potentially
eligible, and individuals with a 10-year ASCVD risk <5% were
considered not eligible for statin treatment.2
To assess eligibility over time, we reassessed eligibility at
each MESA examination based on updated risk factor data and
recalculation of 10-year ASCVD risk. Individuals were excluded
at each follow-up visit if they had developed ASCVD or started
statin therapy. Of the 4962 individuals included in our study at
baseline, 1062 were excluded at examination 2, 375 at
examination 3, 455 at examination 4, and 1035 at examination
5, leaving 2035 participants who remained free of ASCVD and
not on statin therapy at the time of examination 5.
Assessment of CVD Outcomes During Follow-Up
MESA staff contacted each participant or a family member
about interim hospital admissions, outpatient diagnoses of
ASCVD, and deaths at 9-to-12-month intervals. Follow-up
telephone interviews were completed in 92% of living
participants or relatives of deceased individuals. Medical
records were successfully obtained for 98% of hospitalized
events and 95% of outpatient cardiovascular diagnoses. Two
physicians from the MESA mortality and morbidity review
committee independently adjudicated events. In the event of
a disagreement, a consensus was made by the full committee.
The PCE used for risk calculation in both guidelines
calculates the 10-year risk for hard ASCVD outcomes
including nonfatal myocardial infarction, coronary heart
disease (CHD) death, and fatal or nonfatal stroke. We
therefore used a similar definition for hard ASCVD events.
Hard CHD included myocardial infarction, resuscitated cardiac
arrest, and CHD death. Hard ASCVD included hard CHD
events plus nonfatal and fatal stroke. All CHD included
coronary revascularization in addition to hard CHD events. All
ASCVD included all CHD plus stroke and transient ischemic
attacks. A more detailed description of the follow-up methods
and event classification is available on the MESA website.10
Statistical Analysis
We tabulated baseline characteristics for the total population,
across statin-eligibility categories as definedby theUSPSTF and
ACC/AHA guidelines, and the “discordant” group that was
statin eligible by ACC/AHA but not USPSTF criteria. Continuous
variables were presented as meanSD for normally distributed
data and medians with interquartile ranges for non–normally
distributed data. Categorical data were presented as frequen-
cies and proportions. We calculated changes in statin eligibility
over time, determining changes in the absolute prevalence of
statin eligibility for each guideline at subsequent MESA follow-
up visits as well as relative percentage increases in eligibility
compared with baseline.
Absolute ASCVD event rates were calculated by dividing
the total number of events by total person-years contributed
(expressed per 1000 person-years) based on statin eligibility
categories at the time of the baseline examination. Events
were also presented as total number and proportion of each
statin-eligibility category. Kaplan–Meier survival curves were
constructed for ASCVD events in each statin-eligibility
guideline definition. The log-rank was used to test the equality
of survivor functions among statin-eligibility groups.
Using eligibility categories at the time of the baseline
examination, Cox proportional hazards regression models
were used to model time-to-first event for each ASCVD
outcome including hard ASCVD, all ASCVD, hard CHD, all
CHD, myocardial infarction, and stroke. Using not statin
eligible as the reference group in both guideline definitions,
comparisons of event risk were made between the eligibility
categories. To control for potential confounding, income,
MESA site, and body mass index were included in our
adjusted models. All statistical analyses were conducted
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using STATA 13 (Stata Corp., College Station, TX). A P value of
<0.05 was considered statistically significant.
Results
The baseline characteristics of the 4962 MESA participants
(mean age 59.38.8 years, 47.2% female) included in the
study are shown in Table 1, stratified according to statin
eligibility by the USPSTF and ACC/AHA guidelines. According
to the USPSTF guidelines, 1709 (34.4%) of MESA participants
at the time of the baseline examination were eligible for statin
therapy, 384 (7.7%) were potentially eligible, and 2869
individuals (57.8%) were not eligible. According to ACC/AHA
guidelines, 2436 (49.1%) of MESA participants were statin
eligible, 617 (12.4%) were potentially statin eligible, and 1909
(38.5%) were not eligible for statin therapy.
The changes in the prevalence of statin eligibility over time
according to both guidelines are shown in FigureA. Statin
eligibility increased over the course of the follow-up examina-
tions according to both guidelines, though eligibility according
to ACC/AHA guidelines increasedmore significantly with 59.1%
eligible at examination 5 (20.4% increase from baseline)
compared with 39.1% (13.7% increase) by USPSTF. At exam-
ination 5, only 544 individuals (26.7%) were not statin eligible
according toACC/AHAcomparedwith 1042 individuals (51.2%)
not eligible according to USPSTF guidelines.
Participants eligible by USPSTF recommendations com-
pared with ACC/AHA tended to be older and male with a
higher prevalence of diabetes mellitus, hypertension, and
smoking (Table 1). USPSTF guidelines require at least 1 major
ASCVD risk factor and therefore no participants with zero
major risk factors qualified for statin therapy compared with
266 (10.9% of ACC/AHA eligible participants) who qualified
by ACC/AHA despite having zero major risk factors. Those
eligible by USPSTF were more likely to have significant
subclinical atherosclerosis, with 32.8% having CAC ≥100
compared with 28.9% in those eligible by ACC/AHA.
Additionally, participants eligible by USPSTF were less likely
to have zero CAC as 36.6% of those eligible by USPSTF had
CAC=0 compared with 41.2% of those eligible by ACC/AHA.
The prevalence of CAC=0 and CAC >100 according to
eligibility categories for each guideline is shown in Figure B.
The absolute cardiovascular event rates per 1000 person-
years by statin eligibility categories at baseline according to
the USPSTF and the ACC/AHA guidelines are shown in
Table 2 and Figure C. The median follow-up was 12.4 years
(interquartile ranges 11.8, 12.8). ASCVD event rates varied
significantly according to eligibility categories within either
guideline. ASCVD event rates according to USPSTF criteria
were higher in all 3 eligibility categories compared with ACC/
AHA. Individuals who were eligible for statin therapy by
USPSTF experienced 11.6 (95% confidence interval [CI], 10.2–
13.3) hard ASCVD events per 1000 person-years compared
with a hard ASCVD event rate of 2.8 (95% CI, 2.8–3.5) in
those who were not eligible according to USPSTF. Individuals
eligible according to ACC/AHA experienced 10.0 (95% CI,
8.9–11.3) hard ASCVD events per 1000 person-years com-
pared with 1.8 (95% CI, 1.3–2.4) events in those not eligible
according to ACC/AHA.
The baseline characteristics of the 727 (14.7%) individuals
with “discordant” recommendations who were eligible for
statin therapy according to ACC/AHA guidelines but either
potentially eligible (n=384) or not statin eligible by USPSTF
guidelines (n=343) are also shown in Table 1. Compared with
the total sample, individuals in the discordant group were
older with lower total and LDL-C levels, a lower prevalence of
hypertension and smoking, but a higher prevalence of
diabetes mellitus. Of the 727 individuals in the discordant
group, 145 (19.9%) had CAC >100 while 379 (52.1%) had
CAC=0. The absolute cardiovascular event rates according to
baseline CAC for the discordant group are shown in Table 3.
Overall, the discordant group had a hard ASCVD event rate of
6.5 (95% CI, 4.9–8.5) per 1000 person-years. However, event
rates varied significantly according to baseline CAC, as those
with CAC zero had a hard ASCVD rate of 4.2 (95% CI, 2.7–6.7)
per 1000 patient-years compared with a rate of 12.8 (95% CI,
8.3–19.9) in those with CAC >100.
Discussion
In MESA, we found that statin eligibility according to the 2016
USPSTF guidelines was significantly lower compared with the
2013 ACC/AHA guidelines, with 34% of MESA participants
eligible according to USPSTF guidelines compared with 49%
eligible for a risk-based statin discussion according to the
ACC/AHA guidelines. Statin eligibility in the MESA cohort
increased over time by both guidelines, though the increase
was larger for the ACC/AHA guidelines. As would be expected
because of a higher risk threshold for eligibility, compared
with ACC/AHA, participants eligible by USPSTF had a higher
baseline prevalence of CAC and higher ASCVD event rates
over time. Importantly, the 15% of MESA participants eligible
by ACC/AHA but not USPSTF had modestly elevated ASCVD
event rates that varied significantly according to baseline
CAC, suggesting CAC could aid clinical decision making for
statin therapy in individuals with discordant eligibility.
Applying the USPSTF Guidelines: Implications for
the US Population
The recent NHANES data comparing eligibility between USPSTF
and ACC/AHA guidelines estimated that 36.3% of the US adult
population aged 40 to 75 years without known ASCVD is either
already on a statin or eligible for statin therapy according to the
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Figure. A, Statin eligibility according to USPSTF and ACC/AHA guidelines in
4962 MESA participants at baseline (2000–2002) and in those who remained
free of ASCVD and off of statin therapy during follow-up (through 2012). B, The
prevalence of CAC=0 and CAC ≥100 across statin eligibility categories according
to USPSTF and ACC/AHA guidelines in 4962 MESA participants at baseline. C,
Absolute cardiovascular event rates per 1000 patient-years inMESAparticipants
eligible for statin therapy according to USPSTF and ACC/AHA guidelines as well
as the discordant group who were eligible by ACC/AHA but not USPSTF
guidelines. ACC/AHA indicates American College of Cardiology/American Heart
Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary
artery calcium;CHD, coronary heart disease; CVD, cardiovascular disease;MESA,
Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; USPSTF, United
States Preventive Services Task Force.
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USPSTF guidelines, compared with 45.8% already on a statin or
eligible according to the ACC/AHA guidelines.7 This 9.5%
absolute increase in statin eligibility for primary prevention
equates to an estimated 9 million US adults.
We excluded individuals on statin therapy at baseline but
found similar rates of eligibility according to the 2 guidelines
(34% and 49%). Our data suggest that the discordance between
the 2 guidelines may be higher in older, healthier populations
because in MESA we found a 15% absolute increase in statin
eligibility according to ACC/AHA compared with USPSTF. This
higher prevalence of discordance is likely secondary to the
older age of the MESA cohort (mean age 59 years) compared
with the NHANES analysis (mean age 53 years), thus increas-
ing the prevalence of those with elevated ASCVD risk
regardless of the presence of other major risk factors. More
than 10% of MESA participants eligible for statin therapy
according to ACC/AHA were eligible despite having no major
modifiable ASCVD risk factors. Additionally, the discordance
between the 2 guidelines increased during follow-up, with only
25% of participants not statin eligible according to ACC/AHA
guidelines at MESA examination 5 compared with 50% not
eligible according to USPSTF.
What Is the Ideal Risk Threshold: 7.5% Versus
10%?
Although the 2.5% difference in the risk thresholds between
the 2 guidelines may appear small, our data, in addition to the
prior NHANES data,7 demonstrate that even small differences
in risk thresholds can have substantial implications at a
population level. The USPSTF performed a systematic review
and produced an evidence report that was used to determine
the 10% risk threshold.11 The authors of the USPSTF
guidelines did cite data raising concern that the PCE may
overestimate risk in modern populations as one of the
rationales for choosing the more conservative 10% risk
threshold.12,13 The USPSTF decided to require the presence of
1 major risk factor in addition to the 10% risk threshold
because no randomized controlled trial has included patients
without any major ASCVD risk factors.
Table 2. Absolute Cardiovascular Event Rates Per 1000 Person-Years With 95% CIs by Statin Eligibility According to the USPSTF
and the 2013 ACC Guidelines Over 12-Year Follow-Up of 4962 MESA Participants
ASCVD Events Total (%)
Statin Eligible Potentially Statin Eligible Not Statin Eligible
USPSTF (N=1709) ACC/AHA (N=2436) USPSTF (N=384) ACC/AHA (N=617) USPSTF (N=1048) ACC/AHA (N=1909)
Hard ASCVD 326 (6.6) 11.6 (10.2–13.3) 10.0 (8.9–11.3) 6.1 (4.1–8.9) 4.1 (2.8–5.9) 2.8 (2.3–3.5) 1.8 (1.3–2.4)
All ASCVD 451 (9.0) 16.5 (14.7–18.6) 14.4 (13.0–16.0) 10.3 (7.6–13.9) 5.2 (3.8–7.2) 3.7 (3.1–4.5) 2.4 (1.8–3.1)
Hard CHD 200 (4.0) 7.2 (6.1–8.6) 6.0 (5.1–7.0) 3.5 (2.1–5.8) 2.4 (1.5–3.8) 1.6 (1.3–2.1) 1.2 (0.8–1.7)
All CHD 304 (6.1) 10.8 (9.4–12.5) 9.4 (8.3–10.6) 7.6 (5.4–10.7) 3.5 (2.4–5.2) 2.5 (2.0–3.1) 1.8 (1.3–2.4)
Total MI 150 (3.0) 5.3 (4.4–6.5) 4.4 (3.6–5.2) 2.8 (1.6–4.9) 2.0 (1.2–3.3) 1.3 (0.9–1.7) 1.0 (0.6–1.5)
Total stroke 138 (2.7) 4.7 (3.8–5.8) 4.3 (3.6–5.2) 2.6 (1.4–4.6) 1.7 (0.9–2.9) 1.3 (1.0–1.7) 0.6 (0.4–1.0)
ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CIs, confidence intervals;
MESA, Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; USPSTF, US Preventive Services Task Force.
Table 3. Absolute Cardiovascular Event Rates Per 1000 Person-Years With 95% CIs Over 12 Years of Follow-Up According to
Baseline CAC in 727 MESA Participants Eligible for Statin Therapy by ACC/AHA Guidelines But Not Eligible by USPSTF
Cardiovascular Events All (N=727)* CAC 0 (N=379) CAC 1 to 100 (N=203) CAC >100 (N=145)
All ASCVD N, % 77, 10.6% 24, 6.3% 25, 12.3% 28, 19.2%
Event rate 9.8 (7.8, 12.2) 5.7 (3.8, 8.5) 11.7 (7.9, 17.3) 18.5 (12.8, 26.8)
Hard ASCVD N, % 52, 7.2% 18, 4.8% 14, 6.9% 20, 13.8%
Event rate 6.5 (5.0, 8.5) 4.2 (2.7, 6.7) 6.4 (3.8, 10.8) 12.8 (8.3, 19.9)
All CHD N, % 49, 6.7% 10, 2.6% 18, 8.9% 21, 14.5%
Event rate 6.2 (4.7, 20.9) 2.3 (1.3, 4.4) 8.4 (5.3, 13.3) 13.6 (8.9, 20.9)
Hard CHD N, % 26, 3.6% 6, 1.6% 8, 3.9% 12, 8.3%
Event rate 3.2 (2.2, 4.7) 1.4 (0.63, 3.1) 3.6 (1.8, 7.2) 7.5 (4.3, 13.2)
ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, coronary heart
disease; CIs, confidence intervals; MESA, Multi-Ethnic Study of Atherosclerosis; USPSTF, US Preventive Services Task Force.
*Includes participants who were statin eligible according to the 2013 ACC/AHA guidelines but potentially eligible (n=384) or not eligible (n=343) according to USPSTF guidelines.
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A recent analysis from the Jackson Heart Study demon-
strated that application of USPSTF to a cohort of blacks
resulted in eligibility for 55% of individuals with CAC >0
compared with 69% eligibility in those with CAC >0 according to
ACC/AHA guidelines.14 However, the study also found that
blacks with discordant eligibility appeared to be at relatively
low risk, with 4.1 ASCVD events per 1000 patient-years. In our
multiethnic analysis, we found that individuals with discordant
eligibility appeared to be at intermediate risk, because 20% had
CAC scores >100 and they experienced 6.5% ASCVD events
per 1000 person-years. More than 50% of the discordant group
had a CAC score of zero and event rates varied significantly
according to baseline CAC. Prior research has hypothesized
that CAC could be utilized to more effectively allocate statin
therapy to individuals most likely to benefit.15 The arbitrary
nature of risk thresholds and the lack of definitive trial data for
the utility of CAC as well as in individuals at elevated ASCVD
risk because of age alone highlight the importance of the
clinician–patient risk discussion in making the decision to start
statin therapy.3
Statin Allocation: The Importance of Absolute Risk
We found that ASCVD event rates during follow-up in MESA
varied significantly according to eligibility categories by both
guidelines, with individuals who were statin eligible having an
5-fold increase in ASCVD events compared with those who
were not statin eligible. Both USPSTF and ACC/AHA rely
largely on absolute risk to determine statin eligibility, a
significant paradigm shift from prior Adult Treatment
Panel guidelines (ATP III), which relied more heavily on LDL-
C levels to determine statin eligibility.16
The transition to utilizing absolute risk to determine statin
allocation is evidence based because absolute risk has been
shown to be a much stronger predictor of ASCVD events
compared with LDL-C levels, and the cardiovascular benefit of
statin therapy in randomized controlled trials has largely been
independent of baseline LDL-C.17–21 A recent study from a large
Midwestern cohort of patients who experienced ST-segment–
elevation myocardial infarction demonstrated further evidence
supporting a risk-based approach to statin allocation as
application of the ACC/AHA guidelines, compared with ATP III
guidelines, doubled the prevalence of pre-ST-segment–eleva-
tion myocardial infarction statin eligibility, with 39% of the
cohort statin eligible before ST-segment–elevation myocardial
infarction by ATP III comparedwith 79% being statin eligiblewith
application of ACC/AHA guidelines.22
Potential Opportunities for Improvement
The USPSTF and ACC/AHA guidelines both represent signif-
icant progress towards the optimal population-level allocation
of statin therapy. However, these guidelines do have potential
limitations. The PCE was modeled using data from an era
when the prevalence of ASCVD risk factors and subsequent
ASCVD event rates were significantly higher compared with
more recent data.23 New risk equations based on more
modern data may allow for more accurate risk assessment.
Further risk assessment with CAC testing may provide a more
robust method of individualized risk assessment,24 and CAC
scoring has been hypothesized to more accurately identify
individuals who are likely to benefit from statin therapy.15 In
our study, we found that 37% and 41% of individuals who are
statin eligible by USPSTF and ACC/AHA, respectively, had
zero CAC, a finding associated with low ASCVD rates even in
the presence of traditional ASCVD risk factors.25
Strengths and Limitations
Our analysis has several strengths and limitations. Strengths
include a large, multiethnic, geographically diverse, community-
representative, sex-balanced cohort with data on baseline ASCVD
risk factors and CAC, as well as long-term follow-up with
thoroughly adjudicated ASCVD events. Long-term follow-up with
good participant retention allowed for assessment of statin
eligibility over 10 years of follow-up. Survivor bias and loss to
follow-upmayhave influenced the prevalenceof statin eligibility in
the MESA cohort over time. As discussed above, the PCE
calculator used to determine 10-year ASCVD risk has been shown
to overestimate risk when applied to modern cohorts.12,13
However, how to best calibrate the PCE to modern populations is
still subject to debate and the overestimation of risk was cited by
the USPSTF as one of the reasons for choosing a more
conservative risk threshold for consideration of statin therapy.1
Conclusion
In conclusion, using data from MESA, we found that application
of the USPSTF statin guidelines led to a 15% absolute decrease
in statin eligibility compared with application of the 2013 ACC/
AHA guidelines. Compared with ACC/AHA-eligible participants,
those eligible by USPSTF had a higher prevalence of CAC and
higher ASCVD event rates during follow-up, while those eligible
by ACC/AHA but not USPSTF had a modestly elevated ASCVD
event rate that varied significantly by baseline CAC. Healthcare
providers and organizations should understand that the choice
of which guideline to adopt and if and how to integrate CAC
scoring may have a substantial impact on statin utilization and
subsequent ASCVD outcomes at a population level.
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